{"id":"https://openalex.org/W2497067009","doi":"https://doi.org/10.1158/1538-7445.am2016-ct158","title":"Abstract CT158: Phase I study of ramucirumab, a recombinant human IgG1 monoclonal antibody inhibiting vascular endothelial growth factor receptor-2, in Chinese patients with advanced solid tumors","display_name":"Abstract CT158: Phase I study of ramucirumab, a recombinant human IgG1 monoclonal antibody inhibiting vascular endothelial growth factor receptor-2, in Chinese patients with advanced solid tumors","publication_year":2016,"publication_date":"2016-07-15","ids":{"openalex":"https://openalex.org/W2497067009","doi":"https://doi.org/10.1158/1538-7445.am2016-ct158","mag":"2497067009"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2016-ct158","doi":"https://doi.org/10.1158/1538-7445.am2016-ct158","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2016-ct158","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5106232546","display_name":"Li Jin","orcid":"https://orcid.org/0000-0002-7168-4679","observed_orcids":["https://orcid.org/0000-0002-7168-4679"]},"institutions":[{"id":"https://openalex.org/I4210093194","display_name":"Fudan University Shanghai Cancer Center","ror":"https://ror.org/00my25942","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210093194"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Jin Li","raw_affiliation_strings":["1Fudan University Shanghai Cancer Center, Shanghai, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fudan University Shanghai Cancer Center, Shanghai, China;","institution_ids":["https://openalex.org/I4210093194"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076296804","display_name":"Junning Cao","orcid":"https://orcid.org/0000-0002-3146-9413","observed_orcids":["https://orcid.org/0000-0002-3146-9413"]},"institutions":[{"id":"https://openalex.org/I4210093194","display_name":"Fudan University Shanghai Cancer Center","ror":"https://ror.org/00my25942","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210093194"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Junning Cao","raw_affiliation_strings":["1Fudan University Shanghai Cancer Center, Shanghai, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fudan University Shanghai Cancer Center, Shanghai, China;","institution_ids":["https://openalex.org/I4210093194"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100346128","display_name":"Jin Wang","orcid":"https://orcid.org/0000-0002-0062-2489","observed_orcids":["https://orcid.org/0000-0002-0062-2489"]},"institutions":[{"id":"https://openalex.org/I4210152481","display_name":"Lilly (China)","ror":"https://ror.org/05w1xct55","country_code":"CN","type":"company","lineage":["https://openalex.org/I4210152481"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Jin Wang","raw_affiliation_strings":["2Eli Lilly and Company, Shanghai, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Eli Lilly and Company, Shanghai, China;","institution_ids":["https://openalex.org/I4210152481"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015037933","display_name":"Baoyue Li","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152481","display_name":"Lilly (China)","ror":"https://ror.org/05w1xct55","country_code":"CN","type":"company","lineage":["https://openalex.org/I4210152481"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Baoyue Li","raw_affiliation_strings":["2Eli Lilly and Company, Shanghai, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Eli Lilly and Company, Shanghai, China;","institution_ids":["https://openalex.org/I4210152481"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113831304","display_name":"Haidong Chi","orcid":"https://orcid.org/0009-0006-2795-5255","observed_orcids":["https://orcid.org/0009-0006-2795-5255"]},"institutions":[{"id":"https://openalex.org/I4210152481","display_name":"Lilly (China)","ror":"https://ror.org/05w1xct55","country_code":"CN","type":"company","lineage":["https://openalex.org/I4210152481"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Haidong Chi","raw_affiliation_strings":["2Eli Lilly and Company, Shanghai, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Eli Lilly and Company, Shanghai, China;","institution_ids":["https://openalex.org/I4210152481"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5101483571","display_name":"Ling Gao","orcid":"https://orcid.org/0000-0002-0091-2937","observed_orcids":["https://orcid.org/0000-0002-0091-2937"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ling Gao","raw_affiliation_strings":["3Eli Lilly and Company, Bridgewater, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Eli Lilly and Company, Bridgewater, NJ","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"76","issue":"14_Supplement","first_page":"CT158","last_page":"CT158"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0013000000035390258,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ramucirumab","display_name":"ramucirumab","score":1.0},{"id":"https://openalex.org/keywords/vegfr-2-inhibition","display_name":"VEGFR-2 inhibition","score":0.9259999990463257},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.8859999775886536},{"id":"https://openalex.org/keywords/chinese-patients","display_name":"Chinese patients","score":0.6620000004768372},{"id":"https://openalex.org/keywords/safety","display_name":"safety","score":0.36800000071525574},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.984000027179718},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.8370000123977661},{"id":"https://openalex.org/keywords/proteinuria","display_name":"proteinuria","score":0.7540000081062317},{"id":"https://openalex.org/keywords/hypertension","display_name":"hypertension","score":0.8889999985694885},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.5979999899864197},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.6589999794960022},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.3709999918937683},{"id":"https://openalex.org/keywords/anti-angiogenic-therapy","display_name":"anti-angiogenic therapy","score":0.46299999952316284},{"id":"https://openalex.org/keywords/treatment-emergent-adverse-events","display_name":"treatment-emergent adverse events","score":0.6600000262260437},{"id":"https://openalex.org/keywords/advanced-gastric-cancer","display_name":"advanced gastric cancer","score":0.42800000309944153},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.7979999780654907},{"id":"https://openalex.org/keywords/colorectal-cancer","display_name":"colorectal cancer","score":0.9160000085830688},{"id":"https://openalex.org/keywords/hepatotoxicity","display_name":"hepatotoxicity","score":0.3610000014305115}],"concepts":[{"id":"https://openalex.org/C2779551604","wikidata":"https://www.wikidata.org/wiki/Q7290345","display_name":"Ramucirumab","level":3,"score":0.9700913429260254},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8327808380126953},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.6461163759231567},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6164649128913879},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4806062877178192},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.44763925671577454},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.40724682807922363}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2016-ct158","doi":"https://doi.org/10.1158/1538-7445.am2016-ct158","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2016-ct158","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2125913015","https://openalex.org/W2585319073","https://openalex.org/W2610165232","https://openalex.org/W2153297361","https://openalex.org/W2042540245","https://openalex.org/W2400108681","https://openalex.org/W2021264260","https://openalex.org/W4248483932","https://openalex.org/W2809753038","https://openalex.org/W2145224595"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Ramucirumab":[2,330],"is":[3],"a":[4,85,208,385,441],"recombinant":[5,442],"human":[6,15,443],"IgG1,":[7],"high-affinity,":[8],"neutralizing":[9],"monoclonal":[10,337,445],"antibody":[11,446],"specific":[12],"for":[13,121,155,300,472],"the":[14,66,166,205,303,311,364,379,464,469],"vascular":[16,448],"endothelial":[17,449],"growth":[18,450],"factor":[19,451],"receptor-2":[20],"(VEGFR-2),":[21],"which":[22,94],"potently":[23],"blocks":[24],"binding":[25],"of":[26,33,58,72,173,204,211,302,348,366,378,388,439,463,468],"VEGF":[27],"to":[28,64,77,107,117,146,216,246,295,335,394],"VEGFR-2.":[29],"The":[30,55],"clinical":[31],"benefit":[32],"ramucirumab":[34,73,95],"has":[35],"been":[36],"demonstrated":[37],"in":[38,43,93,150,181,187,193,224,231,249,322,401,453],"several":[39],"Phase":[40,60,90,419,436],"3":[41,102,154,195,228,235],"studies":[42],"patients":[44,109,129,148,175,219,304,380,403,455],"with":[45,110,144,178,207,384,404,456],"gastric":[46],"cancer,":[47,51],"non-small":[48],"cell":[49],"lung":[50],"or":[52,101,105,120],"colorectal":[53],"cancer.":[54],"primary":[56],"objective":[57],"this":[59,418],"1":[61,91,183,223,226,230,420],"trial":[62],"was":[63,84,96,126,139,163,310,398],"establish":[65],"safety":[67],"profile":[68],"and":[69,81,153,199,252,287,355],"pharmacokinetics":[70],"(PK)":[71],"monotherapy,":[74],"when":[75],"administered":[76],"Chinese":[78,108,402,454],"patients.":[79,169],"Patients":[80],"methods:":[82],"This":[83],"single-arm,":[86],"non-randomized,":[87],"open-label,":[88],"dose-escalation,":[89],"study":[92,247,296,367,438],"given":[97],"intravenously":[98],"every":[99],"2":[100,152,189,233],"weeks":[103],"(Q2W":[104],"Q3W)":[106],"advanced":[111,457],"solid":[112,458],"tumors":[113],"that":[114],"were":[115,130,176,298,333],"resistant":[116],"standard":[118,124],"therapy":[119,125],"whom":[122],"no":[123,159,369],"available.":[127],"Eligible":[128],"enrolled":[131],"sequentially":[132],"into":[133],"three":[134],"treatment":[135],"cohorts.":[136],"Dose":[137],"escalation":[138],"based":[140],"on":[141],"3+3":[142],"design,":[143],"expansion":[145],"10":[147,186],"each":[149,201],"Cohort":[151,182,188,194,225,232],"PK":[156,331,406],"data":[157],"if":[158],"maximum":[160],"tolerated":[161,400],"dose":[162],"determined":[164],"after":[165],"first":[167],"3-6":[168],"Results:":[170],"A":[171],"total":[172,341],"28":[174],"treated":[177],"ramucirumab:":[179],"6":[180],"(6mg/kg":[184],"Q2W),":[185],"(10mg/kg":[190],"Q3W),":[191],"12":[192],"(8mg/kg":[196],"Q2W).":[197],"Male":[198],"female":[200],"comprised":[202],"50%":[203],"patients,":[206],"median":[209,386],"age":[210],"57-years":[212],"old":[213],"(ranged":[214],"37":[215],"68).":[217],"Two":[218],"experienced":[220],"dose-limiting":[221],"toxicity:":[222],"(Grade":[227,234],"proteinuria),":[229],"alanine":[236,268],"aminotransferase":[237,263,269],"increased).":[238],"Treatment":[239],"emergent":[240],"adverse":[241,327],"events":[242],"(TEAE)":[243],"possibly":[244,293],"related":[245,294],"drug":[248,297],"any":[250],"grade":[251],"more":[253,314],"frequent":[254,315],"than":[255,316],"20%":[256],"included":[257],"fatigue":[258],"(64.3%),":[259],"hypertension":[260,308],"(53.6%),":[261],"aspartate":[262],"increased":[264,270],"(42.9%),":[265,267],"proteinuria":[266],"(39.3%),":[271],"decreased":[272,282],"appetite":[273],"(28.6%),":[274],"sinus":[275],"bradycardia":[276],"(25.0%),":[277,279],"headache":[278],"platelet":[280],"count":[281],"(21.4%),":[283,286],"mouth":[284],"haemorrhage":[285,320],"epistaxis":[288],"(21.4%).":[289],"Grade":[290],"?3":[291],"AE":[292],"reported":[299],"35.7%":[301],"(n":[305,375],"=":[306,376],"10),":[307],"(25.0%)":[309],"only":[312],"one":[313,323],"5%.":[317],"Upper":[318],"gastrointestinal":[319],"occurred":[321],"patient":[324,370],"as":[325],"serious":[326],"event":[328],"(SAE).":[329],"characteristics":[332,407],"similar":[334,405],"other":[336],"IgG1":[338,444],"antibodies:":[339],"low":[340],"body":[342],"clearance":[343],"(\u223c13-19":[344],"mL/h),":[345],"small":[346],"volume":[347],"distribution":[349],"at":[350],"steady":[351],"state":[352],"(\u223c3-4":[353],"L),":[354],"long":[356],"apparent":[357],"terminal":[358],"elimination":[359],"half-life":[360],"(\u223c6-10":[361],"days).":[362],"At":[363],"time":[365],"completion,":[368],"had":[371,381],"complete/partial":[372],"response,":[373],"64.3%":[374],"18)":[377],"stable":[382],"disease":[383],"duration":[387],"5.55":[389],"months":[390],"(95%":[391],"CI:":[392],"3.38":[393],"7.13":[395],"months).":[396],"Conclusion:Ramucirumab":[397],"well":[399],"from":[408,417],"previous":[409],"studies.":[410],"No":[411],"efficacy":[412],"conclusion":[413],"can":[414],"be":[415],"drawn":[416],"trial.":[421],"Citation":[422],"Format:":[423],"Jin":[424,428],"Li,":[425,431],"Junning":[426],"Cao,":[427],"Wang,":[429],"Baoyue":[430],"Haidong":[432],"Chi,":[433],"Ling":[434],"Gao.":[435],"I":[437],"ramucirumab,":[440],"inhibiting":[447],"receptor-2,":[452],"tumors.":[459],"[abstract].":[460],"In:":[461],"Proceedings":[462],"107th":[465],"Annual":[466],"Meeting":[467],"American":[470],"Association":[471],"Cancer":[473,484],"Research;":[474],"2016":[475],"Apr":[476],"16-20;":[477],"New":[478],"Orleans,":[479],"LA.":[480],"Philadelphia":[481],"(PA):":[482],"AACR;":[483],"Res":[485],"2016;76(14":[486],"Suppl):Abstract":[487],"nr":[488],"CT158.":[489]},"counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2016-08-23T00:00:00"}